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Summary 
 
T cells expressing NK cell receptors (NKR) display rapid MHC-unrestricted 
cytotoxicity and potent cytokine secretion and are thought to play roles in immunity 
against tumors.  We have quantified and characterised NKR+ T cells freshly isolated 
from epithelial and lamina propria layers of duodenum and colon from 16 individuals 
with no evidence of gastrointestinal disease and from tumor and uninvolved tissue 
from 19 patients with colorectal cancer.  NKR+ T cell subpopulations were 
differentially distributed in different intestinal compartments and CD161+ T cells 
accounted for over one half of T cells at all locations tested.  Most intestinal CD161+ 
T cells expressed αβ-TCRs and either CD4 or CD8.  Significant proportions 
expressed HLA-DR, CD69 and Fas ligand.  Upon stimulation in vitro, CD161+ T cells 
produced IFN-γ and TNF-α, but not IL-4.  NKT cells expressing Vα24Vβ11+ TCRs, 
that recognize CD1d, were virtually absent from the intestine, however, colonic cells 
produced IFN-γ in response to the NKT cell agonist ligand, α-galactosylceramide.  
NKR+ T cells were not expanded in colonic tumors compared to adjacent uninvolved 
tissue.  The predominance, heterogeneity and differential distribution of NKR+ T cells 
at different intestinal locations suggests that they are central to intestinal immunity. 
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1   Introduction 
 
A minor subset of murine and human T cells express NK cell receptors 
(NKRs) and display functional characteristics of NK cells and classical T cells [1-4].  
NKR+ T cells become activated rapidly after stimulation, are capable of MHC-
unrestricted cytotoxicity in vitro and can secrete large amounts of cytokines including 
IFN-γ, TNF-α, IL-2 and IL-4 [5-7]. They account for about 5% of peripheral blood 
lymphocytes but are enriched in liver and bone marrow, accounting for 35-50% of 
lymphocytes in these organs [8,9]. NKRs can act as inhibitory molecules on cloned T 
cells as shown by in vitro models in CD3-TCR mediated cytolysis [10,11].  Recently, 
NKR+ T cells which recognise HLA-E molecules in association with peptides derived 
from class I MHC molecules or viruses were described [12]. Although the 
mechanisms that control the expression of NKRs on T cells are not well understood, 
these receptors are believed to function as co-stimulatory molecules or to regulate 
effector T cell activity [13-16]. 
 
In mice, the majority of NKR+ T cells are NKT cells.  NKT cells express NK1.1 and 
an invariant TCR α-chain, Vα14Jα18 (formerly Vα14Jα281), which preferentially 
pairs with a limited number of β chains and recognises glycolipid antigens presented 
by the MHC class-I-like protein CD1d [17-19].  The natural ligand(s) for NKT cells is 
unknown, but they respond to α-galactosylceramide (α-GalCer), an extract of the 
marine sponge Agelas mauritanius in a CD1d-restricted manner [20,21].  NKT cells 
play key roles in immunity against tumors in some murine models.  Injection of mice 
with either IL-12 or α-GalCer can result in tumor rejection by a mechanism that is 
dependent upon IFN-γ production and/or anti-tumor cytotoxicity by NKT cells 
[22,23].  Furthermore, mice deficient in NKT cells fail to mediate IL-12-induced 
rejection of tumors [24]. 
 
CD1d-restricted NKT cells expressing invariant Vα24Jα18+ TCR α-chains (formerly 
Vα24JαQ) paired with Vβ11 have been identified in humans [25,26], but they are 
found in much lower numbers in blood (~0.02% of lymphocytes), liver and bone 
marrow (<1%) compared to mice [9, 27].  However, human T cells expressing various 
NKRs, including CD56, CD57, CD161, CD94 and killer Ig-like receptors, have been 
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reported to share functional similarities with invariant NKT cells, such as rapid MHC-
unrestricted cytotoxicity and potent cytokine secretion [3, 4, 7].  Human NKR+ T cells 
are also thought to play roles in anti-tumor immunity [5, 28, 29]. 
 
The human gastrointestinal tract contains several phenotypically and functionally 
distinct populations of T cells [30-33].  Many of these cells are thought to play roles 
in anti-tumor immunity.  T cells isolated from the epithelial layer and the lamina 
propria (LP) of the human colon are cytotoxic and kill carcinoma cell lines in vitro 
[34,35] and T cell infiltration into tumor tissue is associated with improved prognosis 
of colonic carcinoma [36,37].  Recent studies have indicated that NKR+ T cells are 
also present in murine and human intestine [38-40], but to date no studies have 
addressed the potential roles of these cells in intestinal cancer.  
 
We have phenotypically and functionally characterised NKR+ T cells in the epithelial 
and LP layers of non-diseased human duodenum and colon and evaluated changes in 
their numbers and phenotypes in patients with colorectal cancer.  Our results indicate 
that distinct subsets of NKR+ T cells, but not invariant NKT cells, accumulate at 
different intestinal locations.  Many of these cells express Fas ligand and markers of 
activation and secrete inflammatory cytokines upon stimulation in vitro.  Colonic 
CD56+, CD57+ and CD161+ T cells were not expanded in tumor tissue compared with 
adjacent uninvolved tissue. 
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2.   Results 
 
2.1 Compartmentalisation of NKR+ T cells in human intestine 
 
Flow cytometric analysis of single cell suspensions prepared from human colon and 
duodenum revealed differential distribution of NKR+ T cell populations in the 
epithelium and LP (Fig. 1A).  Approximately one half of all T cells in both the 
epithelial (median 44.6%) and LP (58.4%) layers of the colon expressed CD161 (Fig. 
1B).  CD56 was expressed by smaller proportions of colonic T cells, being present on 
a median of 35.1% of epithelial layer T cells and on significantly lower numbers 
(22.4%; P<0.05) of LP T cells.  CD57 was expressed by similar proportions of 
colonic epithelial layer (8.2%) and LP (9.8%) T cells as were found in peripheral 
blood (9.6%) (Fig. 1B).  
  
When T cell subpopulations in duodenal tissue samples were examined, CD161 was 
also found to be expressed by the majority of epithelial layer (58.5%) and LP (57.5%) 
T cells (Fig. 1B).  Smaller proportions of T cells expressed CD56, with significantly 
higher levels found in the LP (19.6%) compared with the epithelium (10.9%; P<0.05).  
T cells expressing CD57 were less frequently detected in both the epithelium (4.3%) 
or the lamina propria (12.2%). 
 
The high frequency of CD161+ cells in both epithelial layer and LP of human colon 
and the co-localization of CD161 and CD3 was confirmed by immunohistochemistry 
and double immunofluorescence (Fig. 1 C and D).   
 
2.2 Phenotypic characterisation of intestinal CD161+ T cells 
 
In both human colon and duodenum, CD8 was expressed by the majority of epithelial 
layer CD161+ T cells (89.5 % in colon and 59.9% in duodenum; Fig. 2 A and B) 
while smaller frequencies expressed CD4.  In contrast, CD4 was expressed more 
frequently by CD161+ T cells in the LP (58.5% in colon and 81.2% in duodenum; Fig. 
2A and B).  Less than 5% of epithelial layer and LP CD161+ T cells in both colon and 
duodenum expressed neither CD4 nor CD8, a double negative phenotype commonly 
associated with NKT cells [17].  Analysis of TCR phenotypes indicated that almost all 
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CD161+ T cells in both duodenal and colonic epithelium and LP layers express αβ 
TCRs while less than 3% expressed γδ TCRs (Fig. 2 A and B).  CD56 was expressed 
by <20% of CD161+ T cells at all intestinal locations tested (Fig 2 A and B). 
 
The majority of total colonic CD161+ T cells expressed the early activation marker 
CD69 (median 78.2%) and up to 38.2% (median 18.4%) expressed the late activation 
marker HLA-DR (Fig. 2C).  CD25 was expressed by a smaller proportion of colonic 
CD161+ T cells (median 7.2%).  Significant populations of intestinal CD161- T cells 
also displayed activated phenotypes (Fig. 2C).   Expression of Fas ligand (CD95L) 
was significantly more frequent in CD161+ T cells compared with CD161- T cells 
(14.5% vs 1.8%; P<0.05; Fig. 2C). 
 
2.3  Vα24+Vβ11+ NKT cells in human colon 
 
It has previously been shown that, in most tissues, the co-expression of the Vα24 and 
Vβ11 TCR chains defines invariant CD1d-restricted Vα24Jα18+ NKT cells [25,26, 
41,42].  We used flow cytometry to detect Vα24Jα18+ NKT cells in human colon.  
The percentage of colonic CD3+ T cells that express Vα24 ranged from 0.3 to 3.3% 
(median 1.0% in epithelium and 1.6% in LP; Fig. 3A).  However, these colonic 
epithelial and LP Vα24+ T cells did not co-express the Vβ11 chain.  In the liver, up to 
90% (median 64.2%) of Vα24+ T cells expressed Vβ11 (Fig. 3B) [27].  These data 
indicate that, while up to 1.6% of hepatic T cells express Vα24Vβ11+ TCRs, these 
invariant NKT cells are present in extremely low numbers in the human colon. 
 
Vα24Vβ11+ NKT cells specifically recognize α-GalCer presented by CD1d [41,42], 
which is expressed and is functionally active in the murine and human intestine [43-
46].  We examined reactivity to α-GalCer in the colonic cell preparations by culturing 
1x106 cells with α-GalCer and analysing the culture supernatants for IFN-γ 
production.  Levels of IFN-γ were significantly upregulated by α-GalCer beyond 
levels detected in unstimulated cultures (Fig. 3C). 
 
2.4  Cytokine Production by CD161+ T cells 
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The ability of freshly-isolated colonic epithelial and LP layer CD161- and CD161+ T 
cells to produce cytokines upon stimulation in vitro was assessed by flow cytometric 
analysis of permeabilized cells.  Significant proportions of CD161+ T cells produced 
IFN-γ and TNF-α, but not IL-4 upon activation with PMA and ionomycin (Fig. 4A). 
TNF-α was produced by significantly higher frequencies of CD161+ T cells compared 
with CD161- T cells from colonic epithelium (39.8% versus 21.2%; p<0.05) and LP  
(69.7% versus 57.1%; p<0.05).  In contrast the frequencies of colonic epithelial and 
LP CD161+ and CD161- T cells that produced IFN-γ in response to stimulation were 
similar.  The proportions of both CD161+ T cells and CD161- T cells that produced 
IL-4 upon PMA/I stimulation was <5% in all donors examined (Fig. 4B). 
 
2.5  NKR+ T cells are not expanded in colonic tumour tissue 
 
Immunofluorescence studies on paired tumor and uninvolved colon tissue sections 
from 6 patients with colonic carcinoma (Fig. 1D) revealed that T cell numbers were 
increased in the tumors in 4 patients and decreased in 2.  Medians of 640 and 487 
CD3+ cells/mm2 of tissue were counted in tumor and uninvolved tissue, respectively, 
from 5 patients (p not significant; Fig. 5A).  Flow cytometric analysis of these T cells 
revealed that NKR+ T cells were not expanded in tumors.  The proportions of T cells 
that expressed CD161 and CD56 were significantly reduced in tumors compared with 
adjacent uninvolved tissue (medians 31.9% vs 49.7% for CD161+ T cells and 8.6% vs 
19.9% for CD56+ T cells; p<0.05; Fig. 5B).  However, the absolute numbers of 
CD161+ and CD56+ T cells did not significantly differ in tumors compared with 
adjacent uninvolved mucosa (medians 187 vs 239 and 27 vs 68 cells per mm2, 
respectively; Fig. 5B).  The proportions and absolute numbers of CD57+ T cells were 
also unchanged in colonic tumors (Fig. 5B).  
 
Vα24+ T cells were also compared in tumor tissue and adjacent mucosa in matched 
tissue specimens from 5 patients.  The percentages of Vα24+ T cells in normal 
mucosa were low (0-2%) and the levels remained virtually undetectable in tumor 
tissues (data not shown).   
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3.  Discussion 
 
NKR+ T cells predominantly localise in peripheral tissues and functionally have the 
capacity to rapidly kill tumor cells and to produce cytokines without the need for prior 
priming with antigen [1-9].  We report here that the healthy adult intestine is a site of 
accumulation of several distinct NKR+ T cell populations that are differentially 
distributed in the duodenum and colon and in the epithelial and lamina propria layers.  
In confirmation of previous studies [38,39], we found that CD161+ T cells are 
amongst the most abundant NKR+ T cell population in the intestine.  These cells were 
found to account for approximately one half of all T cells in both the epithelial and LP 
layers of both the duodenum and colon.  Compared to peripheral blood, CD56+ T cell 
numbers are elevated in the LP of the duodenum and colon and the epithelial layer of 
the colon only.  CD57+ T cells were found at similar frequencies in blood and 
intestinal compartments.   
 
Our results indicate that almost all intestinal CD161+ T cells express αβ-TCRs.  They 
can express CD4 or CD8 but the majority in the epithelial layers of both the 
duodenum and colon are CD8+ while CD4+ cells predominate among CD161+ T cells 
in the LP.  CD161+ T cells expressing the double negative CD4-CD8- phenotype 
commonly associated with NKT cells [17-19] were rarely found in all intestinal 
compartments tested.  Colonic CD161- and CD161+ T cells showed similar 
frequencies of expression of the T cell activation markers CD25, CD69 and HLA-DR, 
but CD178 or Fas ligand, was found to be expressed by higher frequencies of CD161+ 
than CD161- T cells in the colon.  Colonic CD161+ like CD161- T cells are capable of 
rapid secretion of IFN-γ and TNF-α but little IL-4 upon stimulation ex vivo with PMA 
and ionomycin.  The percentage of CD161+ T cells capable of producing TNF-α was 
markedly higher when compared with CD161- T cells.  These findings indicate that 
the majority of CD161+ T cells in the intestine produce cytokines of the Th1/Tc1 
profile consistent with a cytotoxic phenotype. 
 
In the present study we show that, while the human intestine contains large numbers 
of NKR+ T cells, very low proportions of these express invariant Vα24Vβ11+ TCR 
chains, that are associated with CD1d restriction.  Similar findings have been reported 
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for murine NKR+ T cells, defined by the co-expression of CD3 and NK1.1, which are 
rare in the small intestine but accumulate in the colon [40].  In contrast to murine 
liver, intestinal NKR+ T cells do not express invariant Vα14Jα18+ TCRs or require 
CD1d for their development [40].  However, CD1d is constitutively expressed by 
murine and human intestinal epithelial cells [43-46] suggesting that other non-
invariant NKT cells may be present in the intestine.  In support of this, we found that 
colonic mononuclear cells released significant amounts of IFN-γ after stimulation 
with α-GalCer in vitro.  α-GalCer reactivity by human IELs has also recently been 
demonstrated by Van de Wal and co-workers [43], who showed that ligand 
recognition is CD1d-dependent.  The α-GalCer reactive T cells in human colon could 
either be invariant Vα24Jα18+ NKT cells that are present in very low numbers but 
can rapidly activate other cells such as NK cells and conventional T cells, to produce 
IFN-γ.  Alternatively, other non-invariant NKT cells, that recognise α-GalCer 
presented by CD1d, may be present in the colon and may be the primary source of 
IFN-γ.  Non-invariant CD1d-restricted NKT cells that express CD56 and/or CD161 
have been detected in human bone marrow [9] and in hepatitis C virus-infected liver 
[47].  However, recent studies using CD1d-α-GalCer tetramers have provided 
evidence that α-GalCer reactivity is restricted to Vα24Vβ11+ NKT cells [41,42], 
which would argue against the notion of non-invariant hepatic NKT cells 
recognising α-GalCer.  NKT cells reactive with CD1 isotypes that are not found in 
mice, namely CD1a, CD1b and CD1c [18], may also reside within the CD56+/CD161+ 
T cell compartment of the intestine.   
 
CD56+ and CD161+ T cells can participate in antitumor immune responses, being 
capable of potent antitumor cytolytic activity and the production of large amounts of 
inflammatory cytokines in vitro [5-7].  Flow cytometric analysis of lymphocytes 
isolated from tumors and adjacent histologically-normal colonic tissue from 19 
patients showed that the proportions of T cells that express CD56 or CD161 were 
significantly reduced in tumors.  While, their overall numbers were also found to be 
reduced in tumors of 4 of 5 patients, this reduction was not significant.  We also found 
that CD161+ T cells more frequently expressed Fas ligand and produced more TNF-α 
than CD161- T cells, suggesting that they are specialised for anti-tumor cytotoxicity.  
Our observations that NKR+ T cells are not expanded in tumours are not consistent 
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with a role for these cells in tumor immunity, however, the reduction in the 
proportions of NKR+ T cells could result in insufficient activation of NK or cytolytic 
T cells required for efficient clearing of tumor cells [48].  Alternatively, it could be 
the result of activation induced cell death of tumor infiltrating lymphocytes.  
Previously, apoptosis of tumor infiltrating lymphocytes was found to correlate with 
lymph node metastases and poor prognosis in primary colorectal cancer [49].  
Changes in human NKR+ T cell numbers, phenotypes and functions have also been 
described in other malignancies [27-29, 50] although their importance is less clear 
compared with studies in mice [22-24]. 
 
In conclusion, this study has shown that the human intestine is a site where CD161+ T 
cells preferentially accumulate suggesting that these cells are important in local 
immunity including resistance to tumor cell invasion.  These cells frequently express 
Fas ligand and produce IFN-γ and TNF-α in response to stimulation.  Very small 
numbers of these cells express invariant Vα24Vβ11+ TCRs but reactivity against  α-
GalCer is detectable amongst colonic cells, suggesting the presence of other CD1d-
restricted NKT cells.  
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4   Materials and Methods 
 
4.1 Subjects 
 
Sixteen patients (9 females and 7 males; mean age 45 years; range 24-69 years) who 
were being investigated for upper gastrointestinal symptoms were studied. Small 
intestinal disease was excluded by endoscopy and routine histology.  Nineteen 
patients (11 females and 8 males; mean age 69 years; range 56-84 years) with 
colorectal cancer were studied.  All endoscopic samples were obtained with informed 
consent and the study was approved by the Research and Ethics committee of St. 
Vincent’s University Hospital, Dublin. 
 
4.2  Preparation of intestinal cells 
 
Single cell suspensions of epithelial layer and lamina propria were prepared from 
colonic and duodenal biopsy specimens as previously described [51,52].  Briefly, 
biopsy samples were rotated for 1 hr at 37oC in calcium- and magnesium-free Hanks 
Balanced Salt Solution (Gibco-BRL, Paisley, UK) supplemented with 5% FCS, 1 mM 
DTT and 1 mM EDTA.  This results in the removal of the epithelial layer leaving the 
lamina propria intact and attached to the basement membrane.  The resulting single 
cell suspension was washed in RPMI-1640 medium supplemented with 10% FCS and 
antibiotics and viable cells were enumerated by ethidium bromide and acridine orange 
staining.  To obtain LP cells, the remaining mucosal tissue was placed in 5 ml of 
supplemented RPMI-1640 medium containing 130 U/ml collagenase (Type 1A, 
Sigma-Aldrich, Ireland) and rotated for 3 hr at 37˚C.  The resulting single cell 
suspension was washed in RPMI-1640 medium and viability counts were performed 
as above.   
 
Surgically-resected intestinal tissue, which included uninvolved colonic mucosa as 
well as tumor tissue, was prepared similarly except the tissue specimens were first cut 
into fine pieces using a sterile scalpel and then treated with 200 U/ml collagenase.  
The samples were subsequently filtered through a nylon mesh and washed in RPMI 
medium containing 10% FCS.  Cell number and viability were determined as above. 
 11
NK receptor-positive T cells in human intestine.  O’Keeffe et al. 
 
Peripheral blood mononuclear cells were prepared by standard density gradient 
centrifugation (Lymphoprep, Nycomed Pharma, Oslo, Norway). 
  
4.3  Antibodies and flow cytometry 
 
Fluorochrome labelled monoclonal antibodies (mAbs) specific for human CD3, CD4, 
CD8, CD56, CD57, CD161, αβTCR, γδ TCR, HLA-DR, CD25, Fas ligand, IFN-γ, 
TNF-α, IL-4 and isotype matched controls were obtained from BD Pharmingen 
(Oxford, UK).   Monoclonal anti-Vα24 and anti-Vβ11 antibodies were obtained from 
Coulter Immunotech (Marseilles, France).  Single cell suspensions (1 x 105) derived 
from intestinal tissue and peripheral blood were stained using specific mAbs as 
previously described [8, 51, 52] and analysed by flow cytometry using a FACScan 
and CellQuest lysis software (Becton Dickinson).  
 
For measurement of intracellular cytokines (IFN-γ, TNF-α, IL-4) freshly-isolated 
intestinal cell suspensions were stimulated with 10 ng/ml PMA and 1 µg/ml 
ionomycin (Sigma-Aldrich) for 4 hours at 37ºC in the presence of 10 µg/ml brefeldin 
A (Sigma-Aldrich).  Cells were stained for surface expression of CD161 and CD3 and 
subsequently fixed and permeabilised before staining with mAb specific for the 
cytokines and analysing by flow cytometry, as described previously [9]. 
 
4.4  Immunohistochemistry and immunofluorescence 
 
For immunohistochemical staining, resected colonic tissue specimens were fixed in 
formalin and embedded in paraffin.  Sections were subsequently dewaxed, microwave 
heated (3 x 5 mins at 750W in buffer containing 0.1M sodium citrate and 0.1M citric 
acid, pH 6), rinsed in PBS and then incubated with monoclonal anti-CD161 (5 µg/ml) 
(Serotec, Oxford, UK), or with isotype-matched control antibodies.  Staining was 
revealed with a Vectstain Elite kit (Vector laboratories, Peterborough, UK) and 
indirect immunoperoxidase staining.   
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For immunofluorescence studies, biopsy specimens were mounted in cryopreservative 
embedding (OCT, Tissue Tec, Finetec Europe, The Netherlands) and snap frozen in 
liquid nitrogen.  Serial sections, cut at 5µm, were labelled with monoclonal 50 µg/ml 
anti-CD161, 50 µg/ml polyclonal anti-CD3 (Dako, Ely, UK) or with isotype matched 
control antibodies.  Secondary antibodies consisted of Cy3-labelled goat anti-biotin 
(Sigma-Aldrich) for CD161 and anti-rabbit FITC (Sigma-Aldrich) for CD3.  
Fluorescent microscopy was performed on a Nikon TE300 microscope.    
 
4.5 Cytokine response to α-GalCer 
 
Reactivity to 106 intestinal cells were cultured in 24-well tissue culture plates in the 
presence of 100 ng α -GalCer (Kirin Pharmaceutical Research Laboratory, Gunma, 
Japan) [13-15], PHA, or vehicle as control.  After 48 hours incubation, culture 
supernatants were collected and IFN-γ and production were assayed by ELISA 
according to the manufacturer’s instructions (R&D Systems, Oxon, UK). 
 
4.6 Statistical Analyses 
 
Flow cytometric results were expressed as the median values and range.  The Mann-
Whitney U test for non-parametric data was used to analyse results.  P values of less 
than 0.05 were considered significant.  
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Legends to figures 
 
Figure 1.  NK receptor-positive T cells accumulate in the human intestine.  A, Flow 
cytometric analysis of the co-expression of CD3 with CD56, CD57 or CD161 
expression by gated lymphocytes from a non-diseased colon specimen. The numbers 
in the upper right hand quadrants show the percentages of CD3+ cells that express 
CD56, CD57 or CD161.   B, Percentages of CD3+ cells that express CD56, CD57 or 
CD161 in the epithelial (E) and lamina propria (LP) layers of human colon (top, n=8) 
and duodenum (middle, n=10) and in peripheral blood (bottom, n=7).  Horizontal bars 
indicate the median values. C, Localisation of CD161+ cells by immunohistochemical 
staining in normal colonic mucosa. CD161+ cells are indicated by brown staining 
(x200 magnification).  D, Immunofluorescence staining for CD3+CD161+ T cells in 
normal colon.  Positive staining is indicated by the greenish-yellow staining (x400 
magnification). 
 
Figure 2.  Phenotypic characterisation of CD161+ T cells freshly isolated from human 
intestine.  A and B, Percentages of CD3+CD161+ lymphocytes that express CD8, 
CD4, double negative CD8-CD4- (DN), αβTCR, γδTCR and CD56 in the epithelial 
and lamina propria (LP) layers of human colon (A, n=7) and duodenum (B, n=5).  C, 
Percentages of total CD3+CD161+ and CD3+CD161- lymphocytes from normal colon 
(n=7) expressing HLA-DR, CD25, CD69 and Fas ligand. Horizontal bars indicate 
median values. 
 
Figure 3.  Invariant NKT cells do not accumulate in the human colon.  A, Percentages 
of CD3+ cells that express Vα24 (left) and Vα24Vβ11 (right) TCR chains in 
epithelial (E) and lamina propria (LP) layers of human colon (n=7) and blood (n=4). 
Horizontal bars indicate median values.  B, Representative flow cytometry dot plots 
showing Vα24 and Vβ11 TCR chain expression by gated CD3+ cells freshly isolated 
from normal colon, blood and liver. Numbers show percentages of CD3+ cells that 
express the Vα24Vβ11 TCR.  C, Mean IFN-γ  levels released by unstimulated, α-
GalCer-stimulated and PHA-stimulated total colonic cells (n=5). *P<0.05 
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Figure 4.  Intracellular cytokine production by CD161+ and CD161- T cells from 
normal colonic epithelium (E) and lamina propria (LP).  A, Representative flow 
cytometry dot plot showing IFN-γ, TNF-α and IL-4 expression by colonic CD161+ T 
cells stimulated for 4 hours with PMA and ionomycin. The percentages of CD161+ 
cells that express the cytokines are indicated in the upper right quadrants.  B, Median 
percentages of CD161+ and CD161- cells from epithelial and lamina propria layers of 
9 normal colonic specimens that express IFN-γ, TNF-α and IL-4 upon stimulation.  
*P<0.05.   
 
Figure 5.  Colonic NKR+ T cells are not expanded in colonic cancer.  A, 
Quantification of CD3+ cells per mm2 of paired colonic carcinoma and adjacent 
uninvolved colonic mucosa tissue sections in 5 patients using immunohistochemistry.  
B, Percentages (left) and absolute numbers (right) of CD3+ cells that express CD161, 
CD56 or CD57 in paired specimens of tumor involved tissue and adjacent uninvolved 
mucosa.   Horizontal bars indicate the median values.  N=19 for percentages; n=5 for 
absolute numbers; *P<0.05.   
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